EP2976360
MEÐFERÐ MEÐ MÓTEFNUM GEGN CLAUDIN 18.2 Í MEÐFERÐ VIÐ KRABBAMEINI
Status:
EP Einkaleyfi fallið úr gildiEP appl. date:
17.3.2014EP published:
27.11.2019EP application number:
14714586.6
EP translation filed:
14.1.2020Grant published:
15.2.2020EPO information:
European Patent Register
Max expiry date:
16.3.2034Expiry date:
16.3.2025
Title:
THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER
Timeline
Today
17.3.2014EP application
27.11.2019EP Publication
14.1.2020Translation submitted
15.2.2020Registration published
16.3.2025Expires
Owner
Name:
Astellas Pharma Inc.Address:
5-1, Nihonbashi-Honcho 2-Chome, 103-8411, Chuo-kuTokyo, JP
Name:
TRON - Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg- Universität Mainz gemeinnützige GmbHAddress:
Freiligrathstrasse 12, 55131, Mainz, DE
Inventor
Name:
SAHIN, UgurAddress:
Mainz, DE
Name:
TÜRECI, ÖzlemAddress:
Mainz, DE
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113, Reykjavík,
Priority
Number:
PCT/EP2013/000817Date:
18.3.2013Country:
WO
Classification
Categories:
C07K 16/28, C07K 16/30, A61K 39/395, A61P 35/00
Annual fees
Number
Paid
Expires
Payer
Number: 7
Paid: 18.3.2020
Expires: 16.3.2021
Payer: Sigurjónsson & Thor ehf.
Number: 8
Paid: 2.3.2021
Expires: 16.3.2022
Payer: Sigurjónsson & Thor ehf.
Number: 9
Paid: 2.3.2022
Expires: 16.3.2023
Payer: Patice ehf.
Number: 10
Paid: 9.3.2023
Expires: 16.3.2024
Payer: Árnason Faktor ehf.
Number: 11
Paid: 6.3.2024
Expires: 16.3.2025
Payer: Árnason Faktor ehf.